Brain-Computer Interface Clinical Trials Face Resource Constraints as Companies Move Downstream to Recruit Subjects Across Multiple Locations
20 hour ago / Read about 0 minute
Author:小编   

The brain-computer interface (BCI) industry is placing growing emphasis on clinical and patient resources, the importance of which has now surpassed that of funding. With tightly scheduled ethics approvals at top-tier tertiary hospitals in first-tier cities, limited PI availability, and other constrained clinical resources, a large number of projects remain queued and waiting. Companies have begun shifting their clinical trial deployment downstream to provincial-, prefecture-, and county-level hospitals, with primary hospitals in multiple locations successively launching related clinical research and subject recruitment. However, clinical thresholds have not been lowered, and regulatory requirements have become stricter. Although leading hospitals are expanding their clinical translation capacity, they still struggle to keep pace with explosive demand, and patient enrollment efficiency remains low. Amid industry competition, companies are racing to secure IPO windows and financing milestones, and anxiety has spread upstream along the industrial chain, driving capital toward suppliers such as chipmakers and precision manufacturers. Demand for outsourced services, including related CROs and SMOs, has surged, and various regions are pursuing industrial layouts around scarce clinical resources. The core of the BCI race has shifted to capturing clinical resources, while clinical evidence still needs to be accumulated gradually.